Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Glasgow | OTHER |
Not provided
Not provided
Not provided
Not provided
Crohn's disease increases the risk of poor musculoskeletal health, as the inflammatory disease process directly inhibits regulatory pathways involved in bone and muscle formation and maintenance. The negative effects of disease on muscle-bone health are compounded by poor nutritional status, vitamin d deficiency, prolonged exposure to glucocorticoid therapy, and reduced physical activity. Modern, steroid sparing therapies are successful at inducing clinical remission in terms of inflammation, however they have limited effect in remedying observed muscle-bone deficits. Subsequently, patients with Crohn's disease are at increased lifelong risk of pathological fractures and osteoporosis. Novel adjunctive therapies are therefore required to complement pharmacological treatments and target muscle-bone deficits, which are responsible for significant disease burden in Crohn's.
High-impact exercise may be a useful additional therapy for patients with Crohn's disease, as the mechanical strains produced during this type of exercise, through large magnitude muscular contractions and ground reaction forces, can promote bone formation and gains in muscle mass. There have been no previous studies assessing the effects of high impact exercise in Crohn's disease, so it is unknown if this type of exercise is safe and feasible in this population. The aim of this study is to assess the feasibility of high-impact exercise for improving markers of bone and muscle health in adults with Crohn's disease, and compare the effects of exercise with a group of healthy age and sex matched controls.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Crohn's Disease | Experimental | Twelve week jumping based exercise intervention |
|
| Controls | Active Comparator | Age and sex matched controls will undertake the same twelve week intervention for active comparison between groups |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| High-impact exercise intervention | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of participation in high-impact exercise: proportion of exercise sessions completed, and proportion of repetitions completed across intervention | Adherence to exercise intervention - measured as proportion of exercise sessions completed, and proportion of repetitions completed across intervention. | Through intervention period (4 weeks). |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Tibia Bone Density & Geometry | Peripheral quantitative computed tomography (pQCT) | Assessed at baseline (pre-intervention) and follow up (<14 days post-intervention) |
| Change in Whole Body Bone Density & Composition |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lewis Steell | Contact | 01414515841 | lewis.steell@glasgow.ac.uk | |
| Jarod Wong | Contact | 01414515841 | jarod.wong@glasgow.ac.uk |
| Name | Affiliation | Role |
|---|---|---|
| Jarod Wong | NHS Greater Glasgow & Clyde | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde | Glasgow | G51 4TF | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Case control model
Not provided
Not provided
Not provided
Not provided
|
| Acute response to high-impact exercise | Other |
|
|
Dual energy x-ray absorptiometry scan
| Assessed at baseline (pre-intervention) and follow up (<14 days post-intervention) |
| Change in Inflammatory Cytokines | Pro-inflammatory cytokines in blood (Interleukin [IL-] 1Beta, IL-6, IL-17, Tumour necrosis factor alpha) [all in pg/ml] | Intervention effects: Bloods measured at baseline (pre-intervention), midpoint of intervention (Week 7) and <7 days post-intervention to assess changes. Acute effects of exercise: measured pre-exercise, then 0, 15, 30 and 60 minutes post-exercise |
| Change in Bone Formation Marker | Bone specific alkaline phosphatase [ug/ml] | Intervention effects: Bloods measured at baseline (pre-intervention), midpoint of intervention (Week 7) and <7 days post-intervention to assess changes. Acute effects of exercise: measured pre-exercise, then 0, 15, 30 and 60 minutes post-exercise |
| Change in Bone Resorption Marker | C-telopeptide of type I collagen and Sclerostin [both ng/ml] | Intervention effects: Bloods measured at baseline (pre-intervention), midpoint of intervention (Week 7) and <7 days post-intervention to assess changes. Acute effects of exercise: measured pre-exercise, then 0, 15, 30 and 60 minutes post-exercise |
| Change in Disease Specific Health related quality of life | Inflammatory Bowel Disease Questionnaire (CD Group Only) | Assessed at baseline (pre-intervention), mid-point of intervention (Week 7) and follow up (<7 days post-intervention). Scale 32 - 224; higher score means better quality of life. |
| Change in Health related quality of life | PedsQL Generic Core Scale (CD & Control group) | Assessed at baseline (pre-intervention), mid-point of intervention (Week 7) and follow up (<7 days post-intervention). Scale 0 to 100, higher score equals better quality of life. |
| Change in disease related Fatigue | Inflammatory Bowel Disease Fatigue questionnaire (CD Group) | Assessed at baseline (pre-intervention), mid-point of intervention (Week 7) and follow up (<7 days post-intervention). Scale 0 - 120, lower score equals less problems with fatigue. |
| Change in Fatigue | Multidimensional Fatigue Scale (CD & Control group) | Assessed at baseline (pre-intervention), mid-point of intervention (Week 7) and follow up (<7 days post-intervention). Scale 0 - 100, higher score equals less problems with fatigue. |
| Change in Lower limb muscle function | Jumping Mechanography | Assessed at baseline (pre-intervention), mid-point of intervention (Week 7) and follow up (<7 days post-intervention) |
| Habitual physical activity | Wrist-worn accelerometry | Seven days post-baseline visit. |
| Self-efficacy for exercise: questionnaire | Self-efficacy for exercise questionnaire | Pre-intervention. Self-efficacy for exercise scale: Nine-item scale, score 0-10 per item. Min value 0, Max Value 90. Higher score equals better self-efficacy. |
| Change in Disease activity | Crohn's disease activity index (CD only) | Assessed at baseline (pre-intervention), mid-point of intervention (Week 7) and follow up (<7 days post-intervention). Scale 0 to >450. Score 0-150 = remission, 151-220 = mild disease, 220-450 = moderate disease, >450 = severe disease. |
| Change in Dietary Intake | Three-day estimated weight food diary | Assessed at baseline (pre-intervention), mid-point of intervention (Week 7) and follow up (<7 days post-intervention) |
| Change in Body composition | Bio-electrical impedance (Body mass, Fat Mass, Fat Free Mass [all in kg]) | Assessed at baseline (pre-intervention), mid-point of intervention (Week 7) and follow up (post-intervention) |
| Changes in Inflammatory marker in stool sample | Faecal Calprotectin (ug/g) | Assessed at baseline (pre-intervention), mid-point of intervention (Week 7) and follow up (post-intervention) |
| D007410 | Intestinal Diseases |
| D001519 | Behavior |